A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Lucerastat (Primary)
- Indications Fabry's disease
- Focus Registrational; Therapeutic Use
- Acronyms MODIFY
- Sponsors Idorsia Pharmaceuticals
- 08 Feb 2018 New trial record
- 07 Feb 2018 Status changed from planning to not yet recruiting.
- 06 Feb 2018 According to an Idorsia Pharmaceuticals media release, this trial is expected to begin in first half of 2018.